-
公开(公告)号：US20230330069A1
公开(公告)日：2023-10-19
申请号：US18022963
申请日：2021-08-23
IPC分类号： A61K31/426 , A61P31/14
CPC分类号： A61K31/426 , A61P31/14
摘要： Disclosed is use of thiazolides, such as nitazoxanide and/or tizoxanide, against viruses belonging to the Coronaviridae family, such as viruses belonging to the Orthocoronavirinae subfamily.
-
公开(公告)号：US20220125767A1
公开(公告)日：2022-04-28
申请号：US17491878
申请日：2021-10-01
IPC分类号： A61K31/426 , A61K45/06
摘要： Thiazolide compounds, such as nitazoxanide and/or tizoxanide, may be used against viruses belonging to the Picornaviridae family or the Paramyxoviridae family.
-
公开(公告)号：US11173149B2
公开(公告)日：2021-11-16
申请号：US16605978
申请日：2018-04-17
IPC分类号： A61K31/426
摘要： Provided are methods of treating a disease or condition associated with an increased level of expression of a protein disulfide-isomerase A3 (PDIA3) by administering to a subject with an increased level of expression of PDIA3 a PDIA3-inhibiting effective amount of a thiazolide compound, such as nitazoxanide or tizoxanide. Also provided are methods of screening for therapeutic agents based on PDIA3 inhibition.
-
公开(公告)号：US20200038377A1
公开(公告)日：2020-02-06
申请号：US16605978
申请日：2018-04-17
IPC分类号： A61K31/426
摘要： Provided are methods of treating a disease or condition associated with an increased level of expression of a protein disulfide-isomerase A3 (PDIA3) by administering to a subject with an increased level of expression of PDIA3 a PDI A3-inhibiting effective amount of a thiazolide compound, such as nitazoxanide or tizoxanide. Also provided are methods of screening for therapeutic agents based on PDIA3 inhibition.
-
35.发明授权公开(公告)号：US10100023B2
公开(公告)日：2018-10-16
申请号：US15525658
申请日：2015-11-11
IPC分类号： C07D277/46 , C07D277/58 , A61K31/426 , A61K45/06 , A61K9/20 , A61K9/48
摘要： Prodrugs of tizoxanide, an analog or salt thereof are disclosed. The prodrugs have an ester moiety comprising an amino acid moiety, and increase the bioavailability of the tizoxanide, an analog or salt thereof. Compositions and methods of treating an intracellular protozoan infection, a viral infection or a cancer are also disclosed.
-
公开(公告)号：US20180085353A1
公开(公告)日：2018-03-29
申请号：US15814850
申请日：2017-11-16
IPC分类号： A61K31/426 , A61K9/28 , A61K38/21 , A61K31/7056 , A61K9/48 , A61K9/20 , A61K9/24
CPC分类号： A61K31/426 , A61K9/2086 , A61K9/209 , A61K9/28 , A61K9/284 , A61K9/2853 , A61K9/4808 , A61K31/7056 , A61K38/21 , A61K2300/00
摘要： Solid dosage formulations of nitazoxanide or a nitazoxanide analogue are provided that comprise a controlled release portion and an immediate release portion. The pharmaceutical composition is typically in the form of a bilayer solid oral dosage form comprising (a) a first layer comprising a first quantity of nitazoxanide or analogue thereof in a controlled release formulation; and (b) a second layer comprising a second quantity of nitazoxanide or analogue thereof in an immediate release formulation. Method of using the formulations in the treatment of hepatitis C are also provided.
-
公开(公告)号：USRE46724E1
公开(公告)日：2018-02-20
申请号：US15156580
申请日：2016-05-17
IPC分类号： A61K31/415 , A61K31/4168 , A61K31/4196 , A61K31/421 , A61K31/4245 , A61K31/427 , A61K31/433 , C07D231/38 , C07D233/38 , C07D249/14 , C07D261/14 , C07D263/48 , C07D271/07 , C07D285/125 , C07D417/12 , C07D233/88 , C07D233/90 , C07D271/113 , C07D275/03 , C07D277/46 , C07D277/56 , C07D285/08 , C07D285/135 , C07D403/06 , C07D403/12 , C07D405/12 , C07D409/06 , C07D413/12 , C07D417/06 , A61K31/506 , A61K31/497 , A61K31/454 , C07D401/12 , A61K45/06 , C07D231/40 , C07D231/44
CPC分类号： C07D417/12 , A61K31/4196 , A61K31/4245 , A61K31/427 , A61K31/433 , A61K31/454 , A61K31/497 , A61K31/506 , A61K45/06 , C07D231/40 , C07D231/44 , C07D233/88 , C07D233/90 , C07D249/14 , C07D261/14 , C07D263/48 , C07D271/07 , C07D271/113 , C07D275/03 , C07D277/46 , C07D277/56 , C07D285/08 , C07D285/135 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/12 , C07D409/06 , C07D413/12 , C07D417/06
摘要： A new class of haloalkyl heteroaryl benzamides is described. These compounds show strong activity against hepatitis viruses.
-
公开(公告)号：US09827227B2
公开(公告)日：2017-11-28
申请号：US15141921
申请日：2016-04-29
IPC分类号： A61K9/24 , A61K31/426 , A61K9/28 , A61K31/7056 , A61K38/21 , A61K9/20 , A61K9/48
CPC分类号： A61K31/426 , A61K9/2086 , A61K9/209 , A61K9/28 , A61K9/284 , A61K9/2853 , A61K9/4808 , A61K31/7056 , A61K38/21 , A61K2300/00
摘要： Solid dosage formulations of nitazoxanide or a nitazoxanide analogue are provided that comprise a controlled release portion and an immediate release portion. The pharmaceutical composition is typically in the form of a bilayer solid oral dosage form comprising (a) a first layer comprising a first quantity of nitazoxanide or analogue thereof in a controlled release formulation; and (b) a second layer comprising a second quantity of nitazoxanide or analogue thereof in an immediate release formulation. Method of using the formulations in the treatment of hepatitis C are also provided.
-
39.发明申请公开(公告)号：US20170334868A1
公开(公告)日：2017-11-23
申请号：US15525658
申请日：2015-11-11
IPC分类号： C07D277/58 , A61K31/426 , A61K9/48 , A61K45/06 , A61K9/20
CPC分类号： C07D277/58 , A61K9/20 , A61K9/48 , A61K31/138 , A61K31/426 , A61K31/506 , A61K31/555 , A61K31/704 , A61K31/7068 , A61K45/06 , A61P31/04 , A61P31/12 , A61P35/00 , C07D277/46 , A61K2300/00
摘要： Prodrugs of tizoxanide, an analogue or salt thereof are disclosed. The prodrugs have an ester moiety comprising an amino acid moiety, and increase the bioavailability of the tizoxanide, an analogue or salt thereof. Compositions and methods of treating an intracellular protozoan infection, a viral infection or a cancer are also disclosed.
-
公开(公告)号：US20170281603A1
公开(公告)日：2017-10-05
申请号：US15474267
申请日：2017-03-30
IPC分类号： A61K31/426 , A61K45/06
CPC分类号： A61K31/426 , A61K45/06 , A61K2300/00
摘要： Thiazolide compounds, such as nitazoxanide and/or tizoxanide, may be used against viruses belonging to the Picornaviridae family or the Paramyxoviridae family.
-
-
-
-
-
-
-
-
-
搜索结果
67 条记录 (耗时 0.032 秒)
